Skip to main content
Caplight Logo









Asceneuron

Asceneuron

Private
LausanneHealthcare & Life Scienceshttps://asceneuron.com/

Last Round

Series C

Jul 16, 2024

Total Funding Raised

$139.53M

Company Overview

Asceneuron is a biotechnology company that develops orally bioavailable therapeutics for neurodegenerative disorders such as Alzheimer's, Parkinson's, and orphan tauopathies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyneurodegenerative diseasetau proteinO-GlcNAcase inhibitorOGA inhibitorAlzheimer's drugdrug discoveryclinical-stage biotechprogressive supranuclear palsyPSPsmall-molecule therapeuticsdisease-modifying therapytau pathologybiotech pipelinepharma licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Asceneuron Comparables

Compare Asceneuron with similar companies based on industry and business-model similarity.

Asceneuron comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Treventis Corporation
84%
Alectos Therapeutics
84%
Oligomerix, Inc.
83%

Asceneuron Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJul 16, 2024
GrantMar 9, 2021
Series ASep 29, 2015
GrantApr 14, 2015
SeedOct 2, 2012

Asceneuron Investors

Notable investors and investment history

Asceneuron investors
InvestorRounds
EQT Life SciencesSeries C
OrbiMedSeries C
Novo HoldingsSeries C
Sofinnova PartnersSeries C, Series A
SR OneSeries A, Series C
Johnson & Johnson Innovation - JJDC, Inc.Series A, Series C
M VenturesSeries A, Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 16, 2024

    $100M round led by Novo Holdings.

  • Sep 29, 2015

    $31M round led by Sofinnova Partners.

Asceneuron Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Asceneuron Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Asceneuron's valuation, stock price, and market status.

Firmographic Details

HeadquartersLausanne
Employee Range9
Year Founded2012
Last FundingJul 16, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?